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signaling system. Th is is notable because 
RSK also phosphorylates BAD on Ser-155 
 ( Figure 2 ). PGE 2 , acting through EP2/
EP4, has been shown to activate Rap1 
through an EPAC signaling pathway; 8 
Rap1 is upstream of MEK / ERK / RSK. In 
unrelated studies, Wang  et al. 9 found that 
EPAC acts coordinately with PKA in renal 
inner medullary collecting duct cells to 
alter urea movement and potentially other 
transport processes that are important for 
renal-cell osmoregulation. While the 
study did not examine the potential 
involvement of PGE 2 , it demonstrated 
that hypertonicity activates the EPAC 
pathway in the inner medulla. When con-
sidered altogether, these studies suggest 
that PGE 2 can modulate BAD activity and 
apoptosis in the renal tubular epithelial 
cells in the inner medulla by activating 
parallel signaling pathways involving 
EPAC and PKA. 
 Although the hypertonicity-induced 
increase in COX-2 activity can antagonize 
the apoptotic action of BAD, the potential 
negative eff ects of COX-2 should not be 
ignored. In situations where increased 
PGE 2 would be detrimental, there are alter-
nate means by which BAD can be phos-
phorylated that off er an alternate control 
of apoptosis for the kidney. 7 Ser-155 can 
be phosphorylated by RSK following acti-
vation of protein kinase C ( Figure 2 ). Phos-
phatidylinositol-3-kinase (PI3K) and 
heat-shock proteins HSP90 and HSP27 
stimulate AKT to inactivate BAD by phos-
phory lating it on Ser-136. 
 In conclusion, the work of K ü per  et al. 2 
provides new insights into the mecha-
nisms responsible for the deleterious 
eff ects of reducing COX-2 activity phar-
macologically or genetically in the kidney, 
by characterizing the key roles of PGE 2 
and BAD in the survival responses of renal 
epithelial cells to hypertonic stress. Th e 
study suggests that inhibition of COX-2 
by NSAIDs could be detrimental to inner 
medullary epithelial cells by increasing 
the pro-apoptotic actions of BAD and 
ultimately cell death. Given the complex-
ity of responses that can be evoked 
by COX-2-generated prostaglandins, 
and the potential for non-prostaglandin-
mediated regulation of BAD function, 
caution should be exercised not to over-
simplify the control of apoptosis in the 
renal medulla and the role of NSAIDs 
in this process. 
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 A new regulator of the vacuolar 
H   +   -ATPase in the kidney 
 Dominique  Eladari 1 , 2 , 3 and  Jacques  Teulon 1   
 Xu  et al. identify Slc26a11, a novel member of the Slc26 anion exchanger 
family, as an electrogenic (Cl   −   ) n / HCO 3 
  −   exchanger. Functional 
characterization of this transporter suggests that Slc26a11 mediates 
classical electroneutral Cl   −   / HCO 3 
  −   exchange but also exhibits an 
electrogenic Cl   −   conductance. In the kidney, Slc26a11 colocalizes with 
the vacuolar H   +   -ATPase in intercalated cells, emphasizing the 
cooperation of the proton pump with chloride transporters. 
 Kidney International (2011)  80, 907 – 909;  doi: 10.1038/ki.2011.220 
 Vacuolar H   +   -ATPases (V-ATPases) are 
large multiprotein complexes that use the 
energy produced by adenosine triphos-
phate (ATP) breakdown to pump protons 
across cell membranes. In eukaryotic 
cells, the V-ATPases are expressed ubiq-
uitously in intracellular organelles, where 
they play a critical role in their acidifi ca-
tion and intracellular traffi  cking. Th ey are 
also present at the plasma membrane of 
some specialized cells, such as osteoclasts 
and kidney epithelial cells, where they 
mediate acidifi cation of the extracellular 
space or are involved in acid – base trans-
port. A large set of published data indi-
cates that Cl   −   channels or transporters 
might infl uence the activity of V-ATPases, 
via several possible mechanisms. 
 In this issue, Xu  et al. 1 identify Slc26a11, 
a member of the Slc26 exchanger super-
family, as a novel partner of the V-ATPase 
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in the kidney, thus giving new insight into 
a complex issue. Th e authors nicely show 
that the Slc26a11 protein, exclusively 
present in the collecting duct, colocalizes 
with the V-ATPase in three diff erent cell 
types: Slc26a11, like the V-ATPase, is api-
cally expressed in A-intercalated cells, 
whereas both proteins are on the basolat-
eral side in B-intercalated cells. In addition, 
some cells, probably representing non-A-, 
non-B-intercalated cells, display colocali-
zation on their apical and basolateral 
membranes. Th is common localization in 
three diff erent types of cells by itself sug-
gests that Slc26a11 and the V-ATPase 
might functionally interact. Indeed, in a 
second set of experiments, the authors 
demonstrate that Slc26a11 expressed into 
COS7 cells activates endo genous V-ATPase 
by a chloride-dependent mechanism. 
 Th e Cl   −   dependence of V-ATPase activ-
ity is generally accepted when it concerns 
intracellular membranes but is more spec-
ulative for the V-ATPase in plasma mem-
branes. However, a few studies have 
proposed a role for Cl   −   conductance in 
the regulation of the V-ATPase in the 
proximal convoluted tubule and the distal 
convoluted tubule. 2,3 Translocation of H   +  
across membranes by V-ATPases is elec-
trogenic. In intracellular organelles, the 
accumulation of positive charges into a 
limited space may generate a large trans-
membrane potential diff erence, resulting 
in pump self-inhibition in the absence of 
an electric shunt. Several Cl   −   transporters 
and channels have been implicated in this 
process, following pioneer observations in 
Golgi vesicles isolated from rat liver, 4 or 
in secretory granules of parathyroid cells, 5 
showing that Cl   −   conductance is strictly 
necessary to V-ATPase activity. The 
molecular identity of the Cl   −   -conducting 
pathways remains elusive. However, CFTR 
and ClC-5, which are widely distributed 
along the nephron, where they colocalize 
largely with the V-ATPase, particularly in 
intracellular organelles, are attractive can-
didates in the kidney. Accordingly, a 
recent study demonstrated that the knock-
down of ClC-5 or CFTR significantly 
decreased V-ATPase-mediated proton 
secretion in isolated proximal tubules. 2 
However, other studies have provided evi-
dence for direct modulation of V-ATPase 
activity by luminal Cl   −   , independent of 
voltage. For instance, acidifi cation of renal 
endosomes 6 or V-ATPase activity in renal 
proximal tubule cells 2 remains dependent 
on the presence of Cl   −   when membrane 
potential diff erence is dissipated artifi -
cially with valinomycin. Th e role of vesic-
ular Cl   −   has been further demonstrated 
in two elegant studies in which ClC-5 and 
ClC-7 were mutated within a single resi-
due to change transport activity from 
Cl   −   / H   +   exchange into uncoupled Cl   −  
conductance. In these studies, the authors 
showed that the mutated ClCs (although 
acting as electric shunts) were not able to 
improve the activity of the V-ATPase to 
higher levels than in animals devoid of 
ClC-5 7 or ClC-7. 8 Th us, the mechanisms 
by which chloride transporters / channels 
can activate the intracellular V-ATPase are 
unclear and may well include modulation 
of the intravesicular Cl   −   concentration, or 
additional unknown mechanisms. 
 Interestingly, whereas most of the 
Slc26a transporters mediate classical Cl   −   /
 anion exchange, Xu  et al. 1 demonstrate 
the existence of two independent modes 
of Cl   −   transport for Slc26a11, electro-
neutral Cl   −   / HCO 3   −   exchange and Cl   −  
conductance, by manipulating transmem-
brane potential. Th e fact of a transporter 
displaying associated conductance prop-
erties has already been reported for the 
Na   +   -HCO 3   −   cotransporter NBCn1, 
which harbors a Na   +   current, 9 and for the 
two glutamate transporters EAAT1 and 
EAAT3, which possess a Cl   −   conduct-
ance. 10 Within the Slc26a11 family, two 
members, Slc26a7 and Slc26a9, display 
Cl   −   channel properties. It is yet unclear, 
since all transporters were expressed in 
heterologous cells for characterization, 
whether these channel-like activities 
refl ect intrinsic properties of these diff er-
ent transporters. Nevertheless, several 
members of the Slc26 family, including 
Slc26a3, Slc26a6, and Slc26a9, have been 
shown to associate and establish a func-
tional cooperation with CFTR. Since pre-
vious reports have shown the potential 
stimulatory effects of CFTR on the 
V-ATPase, it would be worthwhile to test 
whether Slc26a11 chloride conductance 
refl ects an association with CFTR or a 
CFTR-like channel. Th e mechanism by 
which chloride transporters / channels can 
activate the V-ATPase remains unclear. 
As is indicated above, at least two possi-
bilities have been already proposed: (1) 
chloride transporters might act as chap-
erone, regulating the expression of the 
V-ATPase or its interaction with a chan-
nel critical for its function, such as CFTR; 
and (2) chloride ions moving in parallel 
to protons may dissipate the electrical 
gradient across membranes and thereby 
avoid self-limitation of the pump. Xu 
 et al. 1 demonstrate that chloride depletion 
of the cells abolishes the activation of the 
V-ATPase by Slc26a11. Further, they 
demonstrate that the stimulatory eff ect of 
 Figure 1  |  Complex arrangement of ion transport systems in intercalated cells. The newly 
identified Slc26a11 protein is expressed on the same membrane as the H   +   -ATPase, that is, in the 
apical membrane of A-type intercalated cells and in the basolateral membrane of B-intercalated 
cells. It may function as a Cl   −   channel or Cl   −   / HCO 3 
  −   exchanger. Note the presence in these cells of 
other Cl   −   / HCO 3 
  −   exchangers and, on the basolateral membrane, of the ClC-Kb chloride channel. 
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Slc26a11 on the V-ATPase is only mildly 
aff ected by alteration in the membrane 
potential. Taken together, these observa-
tions suggest that the V-ATPase is acti-
vated by intra cellular chloride and put 
forward a critical role of Slc26a11 in mod-
ulating intra cellular Cl   −   . 
 In summary, Xu  et al. 1 have identifi ed a 
possible novel regulator of the V-ATPase 
in renal intercalated cells. Th is study raises 
a number of exciting possibilities for iden-
tifying new regulatory mechanisms of 
renal acidifi cation. Particularly interesting 
is the fact that Slc26a11 may function in 
Cl   −   conductance mode or Cl   −   / HCO 3   −  
exchange mode, under conditions that 
remain to be determined. Incidentally, 
these results also emphasize the complex 
arrangement of transport proteins in the 
various types of intercalated cells, alto-
gether indicating that the functions of 
these cells are not yet totally understood 
( Figure 1 ). 
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 Choice of dialysis modality 
 Rajnish  Mehrotra 1 , 2 
 Few medical decisions have as profound an impact on every aspect of a 
patient ’ s life as the selection of dialysis modality by a patient with end-
stage renal disease. It remains uncertain whether the outcome 
differences seen between hemodialysis and peritoneal dialysis patients, 
if any, in observational studies are attributable to the dialysis modality. 
Such studies, thus, are insufficient to deny patients a choice in selecting 
their dialysis modality. 
 Kidney International (2011)  80, 909 – 911;  doi: 10.1038/ki.2011.262 
 Over the past three decades, scores of sin-
gle-center, multicenter, and national-reg-
istry studies have compared the outcomes 
of end-stage renal disease patients treated 
with hemodialysis (HD) and peritoneal 
dialysis (PD). Even though the results 
have not always been consistent, a few 
common themes emerged from the stud-
ies using cohorts from the 1990s. 1 First, 
although the early risk for death was lower 
in PD patients, the long-term patient and 
technique survival was not as good as 
achieved with HD. Second, the relative 
outcomes varied by age, diabetic status, 
and comorbidity status of patients —
 younger, nondiabetic patients with no 
additional comorbidity treated with PD 
had a considerably lower risk for death 
than those treated with HD, but older 
diabetic PD patients had a higher risk 
for death than the corresponding HD 
patients. 1 These results, however, have 
limited applicability for our current clini-
cal practice, as improvements in outcomes 
of PD patients have outpaced those seen 
with HD. Th us, in contemporary cohorts 
in the United States there is no signifi cant 
diff erence in the 4-, 5-, and 10-year sur-
vival of patients treated with HD or PD. 2,3 
Th e overall equivalency in outcomes with 
the two therapies in more recent cohorts 
has also been reported from Australia, 
New Zealand, Taiwan, and Colombia, 
regions with higher rates of PD utilization 
than seen in the United States. 3 Th e dif-
ferential improvement in outcomes has 
been seen for every subgroup of patient 
such that the higher risk for death in 
the older diabetics has attenuated in 
comparison with earlier cohort periods. 2 
Despite the multitude of these compari-
sons, the central question meant to be 
answered by these studies remains: are any 
of the diff erences in outcomes seen in any 
cohort or any subgroup thereof attribut-
able to the dialysis modality or a result of 
unmeasured diff erences in the character-
istics of the patients who choose a given 
modality? And is it appropriate to use data 
from such observational studies when dis-
cussing the dialysis treatment options 
with an individual patient? 
 It is with this background that one 
should interpret the results of the analyses 
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